Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment
Malignant melanoma has a poor prognosis because of its strong ability to invade tissues and metastasize. Immune checkpoint blockades significantly improve the clinical response in the development of melanoma. However, there are some obstacles to overcome, such as cost and limited application.
Therefore, prospective approaches remain to be exploited. We designed cellular nanovesicles (NVs) expressing PD-1 to reactivate T cells by disrupting the PD-1/PD-L1 immunoinhibitory pathway. Furthermore, siNF90 was wrapped into PD-1 NVs to inhibit the proliferation of tumor cells. Such a dual
target effect is helpful for the treatment of melanoma. In addition, our results showed that treatment with PD-1 @siNF90 NVs inhibited the growth of melanoma tumors and extended the survival time of mice, exhibiting a better effect than PD-1 NVs alone. The data also verified that the percentage
of CD8+ T cells in tumors was highest after PD-1 @siNF90 NVs treatment. To sum up, PD-1 @siNF90 NVs could serve as safe and effective blockers in the treatment of melanoma.
Keywords: Melanoma; NF90; Nanovesicle; PD-1
Document Type: Research Article
Affiliations: 1: State Key Laboratory of Coordination Chemistry Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University Nanjing 210093, Jiangsu, PR China 2: School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, Guangdong, PR China 3: Department of Oral Surgery, Stomatological Hospital, Southern Medical University, Guangzhou 510280, Guangdong, PR China
Publication date: 01 May 2021
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content